BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
CRD-A
Crawford & Company
There isn't enough reported data to score CRD-A yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CRD-A Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
CRD-A's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CRD-A.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CRD-A in the historical PE scenario, which offers more potential upside but is not a forecast.
CRD-A PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $12.00 | — |
| Cheap | 12x | $8.64 | -28% |
| Fair | 19x | $13.43 | +12% |
| Current | 22x | $12.00 | — |
| Expensive | 29x | $21.04 | +75% |
Historical ranges are pointers, not guarantees.
CRD-A's PE is 22x, but its earnings don't support one, so it isn't a reliable read right now.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CRD-A on the outlook, with more favorable revenue expectations.
CRD-A Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CRD-A's earnings to grow and its profitability to improve, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
CRD-A Earnings Per Share
CRD-A and BAC do not have enough comparable growth data to identify a winner.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over CRD-A on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CRD-A on profitability, with a higher operating margin.
CRD-A Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $329.9M | -0.9% |
| Q2 2026 | $330M | -1.4% |
| Q1 2026 | $320.1M | -1% |
| Q4 2025 | $320.1M | -11% |
| Q3 2025 | $332.8M | -2.9% |
| Q2 2025 | $334.6M | +2.4% |
| Q1 2025 | $323.3M | +3.3% |
| Q4 2024 | $358.3M | +12% |
CRD-A's revenue grew through 2022 and has held roughly level since: $330M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +1.1 points |
| Q2 2026 | 6.4% | +1.6 points |
| Q1 2026 | 2.9% | -0.7 points |
| Q4 2025 | -1.3% | -4.6 points |
| Q3 2025 | 6.2% | +1.2 points |
| Q2 2025 | 4.8% | +0.1 points |
| Q1 2025 | 3.6% | +1.6 points |
| Q4 2024 | 3.4% | +3.2 points |
CRD-A's operating margin was 7.3% last quarter, up 1.1 points from the same quarter a year ago, near the top of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
CRD-A Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5M | -83% |
| Q2 2026 | $18.6M | -45% |
| Q1 2026 | $1.4M | +$16.3M |
| Q4 2025 | $46.9M | +26% |
| Q3 2025 | $29.3M | +65% |
| Q2 2025 | $33.6M | +188% |
| Q1 2025 | -$14.9M | +$6.4M |
| Q4 2024 | $37.3M | +9.1% |
CRD-A has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CRD-A on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CRD-A Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -947K shares |
| 1 year | -3.2% | -1.6M shares |
| 3 years | -2.5% | -1.2M shares |
| 5 years | -10% | -5.4M shares |
| Available history | -10% | -5.5M shares |
CRD-A has 48M diluted shares, down 3.2% from a year ago, with $30M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.5M |
| Q2 2026 | $3.5M |
| Q1 2026 | $5.5M |
| Q4 2025 | $7.6M |
| Q3 2025 | $3M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $263,000 |
CRD-A spent $30M buying back its own shares over the past year, about nine times what it spent the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CRD-A Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.9x | Healthy |
CRD-A has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CRD-A Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 37.5 | Neutral |
CRD-A's weekly RSI is 50 (neutral) and its Stochastic is 37 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over CRD-A on valuation relative to its sector.
CRD-A PE vs Financial Services Sector
| Metric | CRD-A | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 65% above |
| PE % | 63 | 63 | Same percentile |
CRD-A is trading at 22x earnings, a 65% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CRD-A Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 2.7% below |
| 20 week MA | $12.3 | 2.3% below |
| 50 week MA | $11.3 | 5.9% above |
| 100 week MA | $11.1 | 7.9% above |
| 200 week MA | $10.5 | 14% above |
CRD-A has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CRD-A Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.1 | $7.49 | -33% |
| 2021 | $7.49 | $7.51 | +0.3% |
| 2022 | $7.51 | $5.55 | -26% |
| 2023 | $5.55 | $13.2 | +137% |
| 2024 | $13.2 | $11.5 | -13% |
| 2025 | $11.5 | $11.9 | +3.6% |
| 2026 YTD | $11.9 | $12.0 | +1.1% |
CRD-A has the edge over BAC on returns for 2026, with the stronger performance.